Stocks · News reference
Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
Purple Biotech's abstract for its lead tri-specific antibody, IM1240, has been accepted for an oral presentation at the upcoming 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers InnovAge Holding (NASDAQ:INNV) shares increased by 10.8% to $11.65 during Tuesday's after-market session. The company's market cap stands at $1.4 billion. The company's, Q4 earnings came out today.
Crude Oil Moves Higher; US Factory Orders Rise In July
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
Why Is Purple Biotech Stock Gaining Wednesday?
Purple Biotech (PPBT) stock surged premarket after receiving a USPTO patent allowance for its CAPTN-3 tri-specific antibody platform.
Purple Biotech shares are trading higher after the company announced the U.S. PTO issued a Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use.